BRKR vs QSI
BRKR: Bruker is a global leader in high-performance analytical instrumentation and diagnostic solutions for life sciences and materials research, enabling structural biology, drug discovery, and scientific innovation at molecular levels. QSI: A proteomics instrumentation and consumables company bringing massively parallel single-molecule protein sequencing to researchers and clinicians through its Platinum platform, with a next-generation Proteus system in development.
Side-by-side fundamentals
| Metric | BRKR | QSI | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $59.74 | $0.80 | |
| Market cap as of 2026-07-23 | $9.1B | $174M | |
| PEG as of 2026-07-23 | 1.67 | n/a | |
| Net margin as of 2026-07-23 | -0.3% | -5605.9% | BRKR higher |
| Gross margin as of 2026-07-23 | +46.7% | +40.0% | BRKR higher |
| Operating margin as of 2026-07-23 | +0.8% | -6211.7% | BRKR higher |
| ROE as of 2026-07-23 | -0.5% | -47.3% | BRKR higher |
| ROA as of 2026-07-23 | -0.2% | -42.7% | BRKR higher |
| Debt / equity as of 2026-07-23 | 0.68 | 0.00 | QSI lower |
| Revenue growth (YoY) as of 2026-07-23 | +0.4% | -46.2% | BRKR higher |
| Revenue CAGR (3y) SEC XBRL | +10.7% | n/a | |
| Dividend yield as of 2026-07-23 | +0.3% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-23 | 1.27 | 3.25 | |
| 1-year return as of 2026-07-22 close | +54.0% | -51.4% | BRKR higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.